Analyse des parts de marché et principaux résultats du traitement du trouble du désir sexuel hypoactif féminin d'ici 2025-2031
Female Hypoactive Sexual Desire Disorder Therapeutics Market Report Analysis
Female Hypoactive Sexual Desire Disorder Therapeutics Market
-
CAGR (2023 - 2031)XX% -
Market Size 2023
US$ XX million -
Market Size 2031
US$ XX Million
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- Allergan plc
- AMAG Pharmaceuticals, Inc.
- Emotional Brain BV
- Endoceutics, Inc.
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Palatin Technologies Inc
- Pivot Pharmaceuticals Inc
- Sprout Pharmaceuticals, Inc.
Regional Overview
- Amérique du Nord
- Europe
- Asie-Pacifique
- Amérique du Sud et centrale
- Moyen-Orient et Afrique
Market Segmentation
By Thérapie
- testostérone
- flibansérine
- buspirone
- bupropion
- bremelanotide
- thérapie cognitivo-comportementale
By Demande
- hospitalisation
- ambulatoire
By Géographie
- Amérique du Nord
- Europe
- Asie-Pacifique
- Amérique du Sud et Centrale
Get Free Sample For